Sökning: WFRF:(Diaz Torne Cesar)
> (2021) >
Metabolomics profil...
Metabolomics profiling predicts outcome of tocilizumab in rheumatoid arthritis: an exploratory study
-
Murillo-Saich, Jessica D. (författare)
-
Diaz-Torne, Cesar (författare)
-
Ortiz, M. Angeles (författare)
-
visa fler...
-
Coras, Roxana (författare)
-
Gil-Alabarse, Paulo (författare)
-
- Pedersen, Anders, 1976 (författare)
- Gothenburg University,Göteborgs universitet,Svenskt NMR-centrum vid Göteborgs universitet,Swedish NMR Centre at Göteborg University
-
Corominas, Hector (författare)
-
Vidal, Silvia (författare)
-
Guma, Monica (författare)
-
visa färre...
-
(creator_code:org_t)
- 2021-08-16
- 2021
- Engelska.
-
Ingår i: Metabolomics. - : Springer Science and Business Media LLC. - 1573-3882 .- 1573-3890. ; 17:9
- Relaterad länk:
-
https://gup.ub.gu.se...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Introduction: To study metabolic signatures can be used to identify predictive biomarkers for a patient's therapeutic response. Objectives: We hypothesized that the characterization of a patients’ metabolic profile, utilizing one-dimensional nuclear magnetic resonance (1H-NMR), may predict a response to tocilizumab in patients with rheumatoid arthritis (RA). Methods: 40 active RA patients meeting the 2010 ACR/EULAR classification criteria initiating treatment with tocilizumab were recruited. Clinical outcomes were determined at baseline, and after six and twelve months of treatment. EULAR response criteria at 6 and 12months to categorize patients as responders and non-responders. Blood was collected at baseline and after six months of tocilizumab therapy. 1H-NMR was used to acquire a spectra of plasma samples. Chenomx NMR suite 8.5 was used for metabolite identification and quantification. SPSS v.27 and MetaboAnalyst 4.0 were used for statistical and pathway analysis. Results: Isobutyrate, 3-hydroxybutyrate, lysine, phenylalanine, sn-glycero-3-phosphocholine, tryptophan and tyrosine were significantly elevated in responders at the baseline. OPLS-DA at baseline partially discriminated between RA responders and non-responders. A multivariate diagnostic model showed that concentrations of 3-hydroxybutyrate and phenylalanine improved the ability to specifically predict responders classifying 77.1% of the patients correctly. At 6months, levels of methylamine, sn-glycero-3-phosphocholine and tryptophan tended to still be low in non-responders. Conclusion: The relationship between plasma metabolic profiles and the clinical response to tocilizumab suggests that 1H-NMR may be a promising tool for RA therapy optimization. More studies are needed to determine if metabolic profiling can predict the response to biological therapies in RA patients.
Ämnesord
- NATURVETENSKAP -- Biologi -- Biokemi och molekylärbiologi (hsv//swe)
- NATURAL SCIENCES -- Biological Sciences -- Biochemistry and Molecular Biology (hsv//eng)
- NATURVETENSKAP -- Kemi -- Analytisk kemi (hsv//swe)
- NATURAL SCIENCES -- Chemical Sciences -- Analytical Chemistry (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinsk bioteknologi -- Annan medicinsk bioteknologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Medical Biotechnology -- Other Medical Biotechnology (hsv//eng)
Nyckelord
- Metabolomic profiling
- NMR
- Rheumatoid arthritis
- Therapeutic response
- Tocilizumab
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas